Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 29, 2026

P&G Announces Fourth Quarter and Fiscal Year 2026 Results

View original at finance.yahoo.com
P&G Announces Fourth Quarter and Fiscal Year 2026 Results Q4 '26: Net Sales +2%; Organic Sales 0%; Diluted EPS -15%; Core EPS -3% FY '26: Net Sales +3%; Organic Sales +1%; Diluted EPS +2%; Core EPS +1% CINCINNATI, July 29, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Fiscal 2026 was a year of foundation building while continuing to grow sales and profit and return high levels of cash to shareowners despite a very challenging geopolitical and economic environment; expects progress in fiscal 2027 by doubling down on strategy, prioritizing the consumer, and funding investments with a strong productivity program.

    60% confidence

Data points we hold from this source

Procter & Gamble · core eps6.89 USD
Procter & Gamble · adjusted free cash flow productivity100 percent
Procter & Gamble · organic sales growth0 percent
Procter & Gamble · operating cash flow19.6 USD
Procter & Gamble · net income16.1 USD
Procter & Gamble · eps6.62 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
P&G Announces Fourth Quarter and Fiscal Year 2026 Results — Source | Via News | ViaNews Market